Health Catalyst (HCAT) HR chief sells shares to cover RSU tax

Rhea-AI Filing Summary

Health Catalyst, Inc. Chief People Officer Linda Llewelyn reported a tax-related share disposition. On March 2, 2026, 13,836 shares of common stock were disposed of at $1.6599 per share to cover tax withholding tied to restricted stock unit vesting. After this mandated “sell to cover” transaction under the company’s equity incentive plans, she held 329,651 shares directly. The footnote clarifies this was not a discretionary trade.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Llewelyn Linda

Role Chief People Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	13,836	$1.6599	$23K

Holdings After Transaction: Common Stock — 329,651 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Llewelyn Linda

(Last) (First) (Middle)

C/O HEALTH CATALYST, INC.

10897 SOUTH RIVER FRONT PARKWAY, #300

(Street)

SOUTH JORDAN UT 84095

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Health Catalyst, Inc. [ HCAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief People Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		F(1)		13,836	D	$1.6599	329,651	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Issuer's Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

Remarks:

	/s/Benjamin Landry, as Attorney-in-Fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did HCAT Chief People Officer Linda Llewelyn report?

Linda Llewelyn reported a tax-withholding share disposition involving 13,836 Health Catalyst common shares. The shares were automatically sold to satisfy tax obligations arising from the vesting of restricted stock units, under the company’s equity incentive plan rules.

Was the HCAT insider transaction by Linda Llewelyn a discretionary sale?

No, the transaction was not a discretionary trade. A footnote explains the sale was mandated as a “sell to cover” transaction to fund tax withholding on vesting restricted stock units, rather than an open-market decision by Llewelyn.

How many Health Catalyst (HCAT) shares were disposed of in this Form 4?

The Form 4 shows a disposition of 13,836 common shares of Health Catalyst. These shares were sold specifically to cover tax withholding obligations tied to restricted stock unit vesting, according to the footnote disclosure provided.

At what price were the disposed HCAT shares transacted for tax withholding?

The disposed shares were transacted at $1.6599 per share. This price applies to the 13,836 shares sold in the tax-withholding transaction associated with the vesting of restricted stock units under Health Catalyst’s equity incentive plans.

How many HCAT shares does Linda Llewelyn hold after the reported transaction?

After the tax-withholding disposition, Linda Llewelyn directly holds 329,651 shares of Health Catalyst common stock. This post-transaction balance reflects her remaining ownership following the mandated “sell to cover” share sale for tax obligations.

What does the footnote in Linda Llewelyn’s HCAT Form 4 explain about the sale?

The footnote explains the sale covered tax withholding obligations from restricted stock unit vesting and was required by Health Catalyst’s equity incentive plans as a “sell to cover” transaction, indicating it was not a voluntary or discretionary stock sale.